Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Peter Kent (NPI 1164406831)

Field	Value
Entity Type	Individual
Organization	Peter Kent
Address	3800 Park Nicollet Blvd
City	St Louis Park
State	MN
ZIP	55416
Taxonomy	Rheumatology Physician
NPI Enumerated	December 6, 2005

Payer Source	Total Paid
Medicare	$1.6M
Medicaid	$0

Key Findings

This provider’s publicly billed footprint is concentrated in Medicare with Total Medicare revenue: $1.6M and no Medicaid billing on file, meaning the provider is effectively single‑payer (Medicare) for public programs. The absence of any Medicaid claims on file should be treated as a material constraint when comparing payer mix or in‑state public program participation.

Revenue is highly concentrated in biologic drug administration: the precomputed top‑3 Medicare codes account for 55.2% of this provider's total Medicare revenue, led by J3380 ($372.3K, 24.2%), J0129 ($273.7K, 17.8%), and J3262 ($203K, 13.2%). These three codes dominate the practice’s Medicare dollars, indicating that a majority of reimbursement derives from high‑cost injectable or infused specialty therapies rather than routine office evaluations.

The code mix indicates an infusion‑and‑biologics operating model rather than a primarily office‑visit practice: high revenue from J3380, J0129, J3262 and measurable revenue from infusion/chemotherapy administration codes such as 96413 ($24.1K), 96365 ($19.6K) and 96415 ($2.5K) point to on‑site drug preparation and infusion services. Combined with significant biologic drug codes, this pattern suggests the provider bills as a clinician who administers and oversees infusible specialty medications.

Competitive standing for the top drug code is relatively strong nationally but described as unremarkable in volume: J3380 ranks #59 of 620 providers nationally (91th percentile; typical, unremarkable volume for this code), so the provider is above the median national rank for vedolizumab administration yet the benchmark text classifies the volume as typical. By contrast, J0129 (abatacept) ranks #618 of 1221 (49th percentile) and J3262 (tocilizumab) ranks #221 of 618 (64th percentile), indicating mixed but generally modest to above‑median standing across the three principal drugs.

There are notable biosimilar and osteoporosis treatment signals in the portfolio: Q5104 (infliximab‑abda) contributes $114.8K (7.5%) and ranks #42 of 178 (77th percentile), while J3111 (romosozumab) contributes $114.2K (7.4%) and J0897 (denosumab) contributes $116.6K (7.6%), together showing the practice also manages bone‑directed biologic therapies alongside rheumatologic immunomodulators. The presence of both originator biologics and biosimilars suggests a mixed formulary or payer mix that includes biosimilar use.

Statistical outliers and high‑percentile administration activity are present in selected low‑revenue codes: J3489 (zoledronic acid) is listed as notably above typical national volume and ranks #66 of 3032 (98th percentile) despite yielding only $2.9K in revenue, and 96365 ranks in the 93th percentile nationally. These tags indicate certain procedures are performed far more frequently than peers on a per‑code basis even when they do not drive large absolute revenue.

Clinical visit billing is a small share of revenue relative to drug administration: 99214 accounts for $38.3K (2.5% of Medicare revenue) with 450 claims, and higher‑level office visits such as 99215 and 99205 are minimal ($4.9K and $1.9K respectively). This reinforces that the practice’s economics are driven primarily by infused and injected therapeutics rather than evaluation-and‑management volume.

The provider has longstanding enrollment with NPI enumerated 2005-12-06 (~21 years ago), suggesting an established practice presence; combined with the specialty taxonomy of Rheumatology Physician and the listed biologic and osteoporosis codes, the data depict a mature rheumatology practice with a substantial infusion and specialty drug component.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

44 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3380	Injection, vedolizumab, intravenous, 1 mg	21,900	$20	$372.3K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	8,050	$30	$273.7K
J3262	Injection, tocilizumab, 1 mg	50,760	$1	$203K
J0897	Injection, denosumab, 1 mg	6,480	$20	$116.6K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	3,960	$30	$114.8K
J3111	Injection, romosozumab-aqqg, 1 mg	14,280	$10	$114.2K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	3,170	$40	$114.1K
J1602	Injection, golimumab, 1 mg, for intravenous use	5,850	$10	$58.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	450	$90	$38.3K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	1,670	$20	$35.1K

Showing 1–10 of 44

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 44 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Peter Kent — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

44 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	4	20	5,330	$30	$242.9K
J3262	3	20	26,440	$1	$147.6K
J1569	8	10	3,220	$30	$137.2K
J1602	14	20	7,050	$10	$112K
J3380	1	30	5,100	$20	$110.1K
J3111	4	10	11,970	$10	$109.8K
J0897	8	90	1,770	$20	$50.8K
Q5104	2	10	1,050	$30	$45.3K
Q5119	5	30	1,380	$20	$29.5K
Q5103	3	10	890	$20	$14.3K

Showing 1–10 of 44

Related Providers

Other providers that share a Tax Identification Number (TIN) with Peter Kent, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Park Nicollet Clinic	MN	Family Medicine Physician	$0	$210M
Group Health, Inc.	MN	Multi-Specialty Clinic/Center	$0	$204M
Regions Hospital	MN	General Acute Care Hospital	$0	$44.4M
Saint Joseph Mercy Livingston Hospital	MI	General Acute Care Hospital	$0	$18.3M
Park Nicollet Methodist Hospital	MN	General Acute Care Hospital	$0	$17.2M
Group Health, Inc.	MN	Multi-Specialty Clinic/Center	$0	$14.8M
Group Health, Inc.	MN	Clinical Medical Laboratory	$2.4M	$11.5M
Group Health, Inc.	MN	Multi-Specialty Clinic/Center	$0	$13M
Tria Orthopaedic Center LLC	MN	Orthopaedic Surgery Physician	$0	$7.3M
Group Health, Inc.	MN	Pediatric Dentistry	$0	$5.6M

Nearby Providers

Other providers in the same ZIP code as Peter Kent, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tactile Systems Technology, Inc	MN	Durable Medical Equipment & Medical Supplies	$0	$97.5M
Associated Clinic Of Psychology Inc	MN	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$72.7M
Blue & White Service Corporation	MN	Taxi	$0	$39M
Iska Inc	MN	Developmentally Disabled Services Day Training Agency	$0	$10.8M
Caring Sisters Home Care Services, Inc	MN	Assisted Living Facility	$0	$8.8M
The Wayside House, Inc	MN	Substance Abuse Rehabilitation Facility	$0	$7.9M
Medical Scanning Consultants PA	MN	Diagnostic Radiology Physician	$0	$7.5M
Life Medical, P.A.	MN	Multi-Specialty Clinic/Center	$0	$4.6M
Surgicare Of Minneapolis Ltd	MN	Ambulatory Surgical Clinic/Center	$1.4M	$0
Elizabeth Miller	MN	Rheumatology Physician	$1.3M	$0

Peter Kent — Billing Profile & Reimbursement Data

Sign up for Peter Kent — Billing Profile & Reimbursement Data policy alerts

Peter Kent — Billing Profile & Reimbursement Data

Sign up for Peter Kent — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References